# Investigating the Absorption, Metabolism and Excretion (AME) of Idalopirdine

> **NCT02415907** · PHASE1 · COMPLETED · sponsor: **H. Lundbeck A/S** · enrollment: 6 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** [ethyl-1-14C]-idalopirdine
- **DRUG:** [benzyl-7-14C]-idalopirdine

## Key facts

- **NCT ID:** NCT02415907
- **Lead sponsor:** H. Lundbeck A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04
- **Primary completion:** 2015-06
- **Final completion:** 2015-06
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2015-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02415907

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02415907, "Investigating the Absorption, Metabolism and Excretion (AME) of Idalopirdine". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02415907. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*